688513.SH
苑东生物
SSE · Healthcare · Biotechnology · CN
CNY 42.91
−5.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.3B | 1.3B | 1.1B | 1.2B |
| Cost of Revenue | 339.4M | 329.5M | 338.4M | 223.3M | 196.0M |
| Gross Profit | 1.0B | 1.0B | 1.0B | 893.8M | 974.5M |
| Operating Expenses | |||||
| R&D Expense | 276.6M | 265.1M | 263.9M | 238.5M | 230.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 104.8M | 101.5M | 107.1M | 98.9M | 90.3M |
| Selling & Marketing Expense | 424.5M | 416.2M | 445.8M | 384.6M | 474.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 818.9M | 792.6M | 823.5M | 728.6M | 803.1M |
| Cost and Expenses | 1.2B | 1.1B | 1.2B | 951.9M | 999.1M |
| Operating Income (EBIT) | 299.5M | 314.6M | 252.0M | 241.7M | 260.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 284.6M | 299.7M | 252.6M | 241.6M | 262.0M |
| Income Tax Expense | 28.4M | 26.1M | 14.4M | 15.1M | 15.5M |
| Bottom Line | |||||
| Net Income | 274.3M | 284.1M | 238.2M | 226.6M | 246.5M |
| Earnings from Cont. Ops | 256.3M | 273.6M | 238.2M | 226.6M | 246.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 274.3M | 284.1M | 238.2M | 226.6M | 246.5M |
| Per Share | |||||
| Basic EPS | CN¥1.56 | CN¥1.63 | CN¥1.36 | CN¥1.28 | CN¥2.05 |
| Diluted EPS | CN¥1.56 | CN¥1.63 | CN¥1.36 | CN¥1.28 | CN¥2.05 |
| Revenue Per Share | CN¥7.71 | CN¥7.64 | CN¥7.71 | CN¥6.31 | CN¥9.73 |
| Shares | |||||
| Basic Shares Outstanding | 175.3M | 174.3M | 175.2M | 177.0M | 120.3M |
| Diluted Shares Outstanding | 175.3M | 174.3M | 175.2M | 177.0M | 120.3M |
| Profitability Metrics | |||||
| EBITDA | — | 408.8M | 336.5M | 316.5M | 320.3M |
| D&A | — | 94.1M | 84.5M | 74.7M | 59.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026